Nuveen
ONC

Nuveen’s BeOne Medicines Ltd ONC Stock Holding History

Nuveen’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.3M Buy
201,062
+4,633
+2% +$1.37M 0.01% 631
2026
Q1 		$58.3M Buy
196,429
+2,305
+1% +$746K 0.02% 582
2025
Q4 		$59M Sell
194,124
-112,387
-37% -$36.8M 0.02% 566
2025
Q3 		$104M Sell
306,511
-37,696
-11% -$11.4M 0.03% 402
2025
Q2 		$83.3M Sell
344,207
-2,244
-0.6% -$550K 0.02% 447
2025
Q1 		$94.3M Sell
346,451
-58,758
-15% -$13.7M 0.03% 407
2024
Q4 		$74.8M Buy
405,209
+242,560
+149% +$49.6M 0.02% 485
2024
Q3 		$36.5M Buy
+162,649
New +$29.3M 0.01% 820
2024
Q1 		– Sell
-63,200
Closed -$11.4M – 3311
2023
Q4 		$11.4M Hold
63,200
– – ﹤0.01% 1515
2023
Q3 		$11.4M Buy
63,200
+10,000
+19% +$1.98M ﹤0.01% 1396
2023
Q2 		$9.49M Buy
53,200
+33,000
+163% +$7.6M ﹤0.01% 1548
2023
Q1 		$4.35M Buy
20,200
+2,200
+12% +$528K ﹤0.01% 1971
2022
Q4 		$3.96M Sell
18,000
-83,516
-82% -$15.3M ﹤0.01% 2049
2022
Q3 		$13.7M Buy
101,516
+4,758
+5% +$817K 0.01% 1280
2022
Q2 		$15.7M Buy
96,758
+1,000
+1% +$156K 0.01% 1221
2022
Q1 		$18.1M Buy
95,758
+25,900
+37% +$5.51M 0.01% 1252
2021
Q4 		$18.9M Buy
69,858
+6,666
+11% +$2.25M 0.01% 1264
2021
Q3 		$22.9M Buy
63,192
+3,038
+5% +$993K 0.01% 1171
2021
Q2 		$20.6M Buy
60,154
+5,462
+10% +$1.81M 0.01% 1339
2021
Q1 		$19M Buy
54,692
+3,190
+6% +$1.06M 0.01% 1360
2020
Q4 		$13.3M Sell
51,502
-7,287
-12% -$2.01M ﹤0.01% 1515
2020
Q3 		$16.8M Sell
58,789
-15,694
-21% -$3.69M 0.01% 1174
2020
Q2 		$14M Buy
74,483
+25,583
+52% +$4.16M 0.01% 1264
2020
Q1 		$6.02M Sell
48,900
-6,900
-12% -$1.08M ﹤0.01% 1605
2019
Q4 		$9.25M Sell
55,800
-10,745
-16% -$1.79M ﹤0.01% 1637
2019
Q3 		$8.15M Sell
66,545
-4,900
-7% -$651K ﹤0.01% 1686
2019
Q2 		$8.86M Buy
+71,445
New +$9.07M ﹤0.01% 1677

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's ONC Position: Q2 2026 in Review

Nuveen increased its BeOne Medicines Ltd (ONC) stake by 2.4% in Q2 2026, buying an estimated $1.37M and bringing the position to 201,062 shares worth $57.3M. The position accounts for 0.01% of the portfolio, ranked #631.

Nuveen first reported a position in ONC in Q2 2019 and has held it in 27 quarters since. The position peaked at $104M in Q3 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Nuveen held 201,062 shares of BeOne Medicines Ltd worth $57.3M as of Q2 2026.
  • Nuveen bought 4,633 BeOne Medicines Ltd shares in Q2 2026, an estimated $1.37M.
  • BeOne Medicines Ltd made up 0.01% of Nuveen's portfolio in Q2 2026, its #631 holding.
  • Nuveen first reported a position in BeOne Medicines Ltd in Q2 2019 and has held it in 27 quarters since.
  • Nuveen's BeOne Medicines Ltd position peaked at $104M in Q3 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.